Piper Sandler raised the firm’s price target on ResMed (RMD) to $275 from $270 and keeps a Neutral rating on the shares. The firm notes the company reported Q2 results that beat estimates on the top-line and bottom-line. Overall, this quarter was solid, but Piper is electing to remain on the sidelines.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: